Su, Kang-Yi
National Taiwan University · National Taiwan University Hospital
4 papers on CoChatORCID 0000-0002-6538-9526
Most cited papers
- Verified
Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 499
- Verified
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
Chen, Y.-J., Roumeliotis, T. I., Chang, Y.-H., Chen, C.-T., Han, C.-L., Lin, M.-H., Chen, H.-W., Chang, G.-C., Chang, Y.-L., Wu, C.-T., et al. (2020) · Cell
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 382
- Verified
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Lin, C.-C., Shih, J.-Y., Yu, C.-J., Ho, C.-C., Liao, W.-Y., Lee, J.-H., Tsai, T.-H., Su, K.-Y., Hsieh, M.-S., Chang, Y.-L., et al. (2018) · The Lancet Respiratory Medicine
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 145
- Verified
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
Chen, L.-Y., Molina-Vila, M. A., Ruan, S.-Y., Su, K.-Y., Liao, W.-Y., Yu, K.-L., Ho, C.-C., Shih, J.-Y., Yu, C.-J., Yang, J. C.-H., et al. (2016) · Lung Cancer
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 67
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free